Emerging therapies for gout.
Rheum Dis Clin North Am
; 40(2): 375-87, 2014 May.
Article
en En
| MEDLINE
| ID: mdl-24703353
Over the past decade much has been learned about the mechanisms of crystal-induced inflammation and renal excretion of uric acid, which has led to more specific targeting of gout therapies and a more potent approach to future management of gout. This article outlines agents being developed for more aggressive lowering of urate and more specific anti-inflammatory activity. The emerging urate-lowering therapies include lesinurad, arhalofenate, ulodesine, and levotofisopam. Novel gout-specific anti-inflammatories include the interleukin-1ß inhibitors anakinra, canakinumab, and rilonacept, the melanocortins, and caspase inhibitors. The historic shortcomings of current gout treatment may, in part, be overcome by these novel approaches.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Uricosúricos
/
Hormona Adrenocorticotrópica
/
Antirreumáticos
/
Melanocortinas
/
Interleucina-1beta
/
Gota
Límite:
Humans
Idioma:
En
Revista:
Rheum Dis Clin North Am
Asunto de la revista:
REUMATOLOGIA
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Estados Unidos